ACADEMIA
Intermolecular Grows IP Portfolio to Over 700 U.S. Patents and Patent Applications
- Written by: Webmaster
- Category: ACADEMIA
Intermolecular announced that its intellectual property (IP) portfolio has increased to 730 U.S. patents and patent applications. The company now owns or has exclusive rights to this portfolio which covers both its HPC innovation platform and the inventions resulting from deploying the platform for the benefit of its customers. The company filed 207 US patent applications in 2011, spanning innovations in semiconductor technology including advanced logic, DRAM, and Non-volatile Memory (NVM), as well as in clean-energy fields such as photovoltaics (PV), light-emitting diodes (LED), and energy-efficient glass.
Intermolecular's HPC (High Productivity Combinatorial) platform includes Tempus(TM) hardware, unique test-vehicle characterization methods, and Informatics analysis software. The HPC platform was developed using fundamental combinatorial processing technologies licensed from Symyx. The IP rights underlying these technologies were acquired by Intermolecular from Symyx as a result of Intermolecular's recent initial public offering of stock on the NASDAQ stock exchange.
"The growth rate of Intermolecular's IP portfolio is a testament to the productivity of our HPC innovation platform and the capabilities of our incredible multi-disciplinary team," said David Lazovsky, founder, president, and chief executive officer of Intermolecular. "We have approximately 150 scientists and engineers in our company, and 111 of these talented individuals submitted a total of 318 invention disclosures in 2011. We continue to enhance our IP protection, both for our HPC platform as well as for the IP we develop with our customers in our Collaborative Development Programs."
IP which has been collaboratively developed with customers may cover new materials, processes, and integrated device structures for semiconductor and clean-energy industries. Intermolecular's customers gain competitive advantage by accelerating time-to-market for their high-value products and by gaining controlling rights to this IP. Intermolecular also generates application-specific IP from strategic internal development initiatives.